Drug Overdose Prevention Newscast

Having trouble viewing this email? View it as a Web page.

New DOP header

April 27, 2021

Here are your weekly updates from the Indiana Department of Health:


Indiana Extends Needle Exchange Authority to 2026

Syringe exchange

In addition to technical assistance, the Indiana Department of Health makes grants to locally approved syringe service programs from federal Centers for Disease Control (CDC) HIV Prevention funds in HEA 1203. Federal and state funds are not used in the purchase of syringes, but may be used for staffing and harm reduction components of the programs.Additional local syringe service programs could be started, or existing programs could be continued with the delay of the sunset provision until July 1, 2026. As of 2019, Indiana had over 8,500 people participating in syringe service programs in nine counties. Syringe service programs promote public health through reducing the transmission of infectious diseases, such as HIV and hepatitis C. People who are participating in syringe service programs are also significantly more likely to enter treatment for substance use disorder.  


Addressing the Overdose Epidemic by Decriminalizing Buprenorphine and Reducing Harm

An article published by the Wayne State University School of Social Work Center for Behavioral Health and Justice says an extensive body of literature supports medication-assisted treatment (MAT) as the gold standard treatment for opioid use disorder (OUD). Three medications have been approved by the U.S. FDA for MAT, buprenorphine, methadone and naltrexone. However, the article says criminalization of low-level buprenorphine possession increases the barriers people with an OUD face as they try to reach treatment and achieve recovery. Only 15% of OUD patients receive medication as a part of their treatment. Research shows that majority of the people who obtain non-prescribed buprenorphine do not misuse it, but rather use it to manage withdrawal symptoms, bridge gaps in treatment and detox. Furthermore, literature shows that buprenorphine taken in any context (with or without prescription) contributes to a reduction in fatal overdoses and an increased adherence to treatment. The decriminalization of buprenorphine in Vermont and Philadelphia has shown a decrease in overdose deaths and increase entry into recovery.


Fake Prescription Pills Sold by Drug Traffickers May Contain Lethal Amounts of Fentanyl

pills

The U.S. Drug Enforcement Agency (DEA) has recently seized a large amount counterfeit pharmaceutical pills in Mexico. These pills were made to look like prescription drugs, such as Adderall, Percocet, Xanax etc. However, the pills were laced with lethal amounts of fentanyl. The DEA stressed that traffickers are trying to fool casual drug users into buying these “prescription drugs.” Traffickers use fentanyl because it is cheaper and easy to make, creating a larger profit for the sellers and makers. As little as 2 milligrams of fentanyl can be fatal for an adult. The DEA warns that any using any non-prescribed pills is extremely dangerous as they have a very high possibility of containing fentanyl.

Follow us! @INDTrauma

twitter

Check out our website:

world wide web logo
light blue divider

UPCOMING EVENTS

light blue divider

Opioid Use Disorder Prevention, Treatment, and Management Virtual Event

Noon – 2:30 p.m. EDT, Wednesday, April 28

The Indiana Rural Opioid Consortium (InROC) is hosting a webinar hosted by Dr. Michael Wheelis, MD. This program can be used for 1 continuing medical education (CME) credit.

Click here to register.

light blue divider

An Overview of Rhode Island Emergency Department Standards of Care for Opioid Use Disorder and Overdose – Part I

2 p.m. – 3 p.m. EDT, Monday, May 10

Dr. Elizabeth Samuels of the Rhode Island Department of Health will go over the models of emergency department treatment standards for opioid overdose and opioid use disorder implemented at Rhode Island hospitals. Dr. Samuels will also discuss her experience with policy implementations and policy adoptions.

Click here to register.

light blue divider

Indiana Opioid Echo - Virtual ECHO Clinic for Treatment of Opioid Use Disorder and Stimulant Use Disorder

Noon – 1 p.m., Wednesdays (Series), January – May 2021

This free TeleECHO clinic aims to teach participants on how to identify and manage patients with opioid use disorder (OUD) and stimulant use disorder (SUD). The goal is to have a team of experts present on information related to medication-assisted treatment and continuity of care increase clinical competence in treating OUD and SUD. It is designed as a drop-in model, so attendance every week is not necessary. Additionally, this is an opportunity to gather CME credits, each session counts for one credit.

Upcoming sessions:

Apr.21 - Harm Reduction Strategies

Click here to register 

light blue divider

Treatment of Opioid Use Disorder in Pregnancy – Project ECHO

Noon - 1:30 p.m. EDT Thursday, March - July 2021

The TeleECHO Clinic has partnered with MOMII (Maternal Opioid Misuse Indiana Initiative) program to promote clinical competence in treating for this complex disease in primary care offices, specifically highlighting evidenced based practices related to Medicated Assisted Treatment and continuity of care. 

Upcoming Webinars

April 29 – Polysubstance Use

Click here to register.